Abstract: The present invention relates to the identification of new peptides and peptidomimetics which bind the CXCR4 receptor, capable of forming complexes with receptors for chemokines, in particular with CXCR4. The invention also relates to the use of these peptides for the treatment, prevention and diagnosis of diseases which involve chemokine receptors (i.e. neoplasias, metastases, HIV-1 virus infections), and also the mobilization of stem cells of hemopoietic precursors in the case of autologous transplants. Finally, the invention comprises pharmaceutical compositions and diagnostic kits comprising said peptides.

Abstract: A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma and epidermoid skin carcinoma.

Abstract: Antibody or fragment thereof, which specifically binds to folate receptor-alpha (FR?), wherein said antibody or fragment thereof comprises a light chain whose variable region comprises at least one of the following amino acid sequences: —RASESVSFLGINLIH (SEQ ID NO: 3), —QASNKDT (SEQ ID NO: 4), —LQSKNFPPYT (SEQ ID NO: 5), and wherein the constant region of said light chain is a kappa constant region.

Abstract: A method for the early diagnosis, prognosis or clinical monitoring of cancer disease based on the quantitation of DNA in a plasma sample from a cancer patient, a subject with cancer susceptibility or an individual at risk of developing cancer.

Abstract: Antibody or fragment thereof, which specifically binds to folate receptor-alpha (FR?), wherein said antibody or fragment thereof comprises a light chain whose variable region comprises at least one of the following amino acid sequences: RASESVSFLGINLIH, (SEQ ID NO: 3) QASNKDT, (SEQ ID NO: 4) LQSKNFPPYT, (SEQ ID NO: 5) and wherein the constant region of said light chain is a kappa constant region.

Abstract: Compounds are disclosed with the general formula in which the groups are as defined in the description here below and characterized by the presence of polyamine substituents on the imine/oxime residue, such amine groups being in turn protected by suitable protective groups. Said compounds are endowed with potent topoisomerase I inhibiting activity and therefore are useful as medicaments for the treatment of tumors and viral and parasite infections.

Abstract: Formula (I) compounds are described: (I) where the groups are as defined in the description here below, the racemic mixtures, their individual enantiomers, their individual diastereoisomers, their mixtures, and their pharmaceutically acceptable salts. Said compounds are topoisomerase I inhibitors.

Abstract: Formula (I) compounds are described: (I) where the groups are as defined in the description here below, the racemic mixtures, their individual enantiomers, their individual diastereoisomers, their mixtures, and their pharmaceutically acceptable salts. Said compounds are topoisomerase I inhibitors.

Abstract: Camptothecin derivatives of camptothecin of formula (I) wherein the groups R1, R2 and R3 are as defined in the description are disclosed. The compounds of formula (I) are endowed with antitumor activity and show a good therapeutic index. Processes for the preparation of the compounds of formula (I) and their use in the preparation of medicaments useful in the treatment of tumors, viral infections and antiplasmodium falciparum are also disclosed.

Abstract: Disclosed are methods for detecting ALK tyrosine kinase activity and for the identification of compounds that modulate ALK activity, peptide substrates, reagents and compositions thereof.

Abstract: Compounds of formula (I), wherein: R1 is —CN, —CH(CN)—R4, —CH═C(CN)—R4, —CH2—CH(CN)—R4, —C(═NOH)—NH2, —C(═NH)—NH2, —CH═C(NO2)—R4, —CH(CN)—R5, —CH(CH2NO2)—R5; 5-tetrazolyl, 2-(4,5-dihydrooxazolyl), 1,2,4-oxadiazolin-3-yl-5-one; R2 is hydrogen; R3 is hydrogen, OR6; R4 is hydrogen, C1-C6 linear or branched alkyl, CN, COOR7; R5 is hydrogen, OR8; R6 is hydrogen, C1-C6 linear or branched alkyl, (C6-C12) aryl (C1-C4) alkyl, (C1-C4) alkoxy (C1-C4) alkyl, (C1-C4) alkyl (C6-C12) aryl, (C6-C12) aryl (C2-C4) acyl, (C2-C4) acyl, amino (C1-C4) alkyl, amino (C2-C4) acyl, glycosyl; R7 is hydrogen, C1-C6 linear or branched alkyl, (C6-C12) aryl (C1-C4) alkyl, (C1-C4) alkoxy (C1-C4) alkyl, (C1-C4) alkyl (C6-C12) aryl; R8 has the same meanings of R6, independently of the latter. These compounds are active as topoisomerase I inhibitors and can be used as antitumor drugs.

Abstract: Anti-anthracycline antibiotic monoclonal antibodies are useful as antidotes of the anthracycline antibiotics themselves, as well as for the treatment of anthracycline extravasation lesions and alopecia.

Abstract: A coated stent, particularly a biocompatible polymeric material coated stent, and a coating process are herein described.

Abstract: The use of 4'-iodo-4'-deoxydoxorubicin and its pharmaceutically acceptable salts in the treatment of amyloidosis is described.

Abstract: Monoclonal antibodies able to selectively bind to doxorubicin and its analogues and derivatives are disclosed.

Abstract: A monoclonal antibody against Doxorubicin and other anthracycline derivatives, being the monoclonal antibody able to selectively recognize epitopes located in correspondence or in proximity of the aromatic D ring of the anthracycline molecule, is described.

Abstract: Kit for use in the determination of the proliferative activity in human tumours, characterized mainly by a container containing, in assembled and lyophilized form, the four basic components (culture medium, antibiotic, serum and radioactive metabolic precursor) necessary to fix the tumoural material fragments rapidly and easily, without any fear of degradation and granting reliable results.